The demand for privacy law expertise continues to increase, as courts and lawmakers wrestle with the issue of what sorts of information are protected under the law, how violations are or should be enforced, what forms of recourse and relief are available to aggrieved parties, and where such relief may be obtained. The Eleventh Circuit
Judge Rebecca F. Doherty entered an amended judgment on October 27, 2014, reducing a $6 billion award of punitive damages against Takeda and a $3 billion award against Eli Lilly in Allen v. Takeda Pharmaceutical Co. Ltd. et al., Civil No. 6:12-cv-00064, a case in the Actos MDL, proceeding in the Western District of Louisiana,
A long-awaited settlement was reached between Howmedica Osteonics Corp., manufacturer of the Stryker Rejuvenate and ABG II hip implants, and representatives for persons injured by these medical devices. The settlement includes encompasses claims brought in both the federal MDL pending in the District of Minnesota ( In re: Stryker Rejuvenate and ABG II Hip Implant
A few weeks ago, the Center for American Progress published a short video detailing the deleterious effects tort reform has on public safety in Texas. Here’s what they had to say about their video: “A new video from Legal Progress, the legal policy program at the Center for American Progress, documents the damaging effects of
Last month, members of the US Congress sent letters to 14 generic drug manufacturers, demanding explanation for the recent, dramatic spike in the price of some 20 generic drugs. The Generic Pharmaceutical Association, a trade group representing the generic pharmaceutical industry, blames the increase on simple market forces, but many are suspicious of that response.
After several states passed tort reform legislation in 2004, the Economic Policy Institute published a report titled “The frivolous case for tort law change: Opponents of the legal system exaggerate its costs, ignore its benefits,” that revealed a number of important flaws in the argument for the necessity for and benefit from tort reform. Many
The recent approval of a drug for use in combating leukemia by the US Food and Drug Administration has shed light on the relatively controversial, albeit common practice by that organization of using surrogate markers of efficacy for determining the benefit of a given drug or therapy. Some believe this constitutes a low bar for
Tort reform has sullied the political landscape of this country for years. A set of proposed laws and regulations at both the state and federal level, one central aim of tort reform is to limit the compensation an injured party can recover in a personal injury lawsuit, or “tort,” attempting to “save” health care from
In January, 2014, an article published in The Journal of Neuropsychiatry and Clinical Neurosciences titled “Long-Term Duloxetine Withdrawal Syndrome and Management in a Depressed Patient” reported on a depressed patient who used Cymbalta (duloxetine), discontinued the drug, and faced long-term withdrawal symptoms. After using Cymbalta (60mg/day) for one year, the patient, called “Miss B” in
WARNING: Xarelto Linked to Fatal Internal Bleeding, No Reversal Agent Recently, the anticoagulant drug Xarelto (rivaroxaban) has come under increased scrutiny by both the United States Food and Drug Administration and medical professionals alike, citing an increased risk for internal bleeding. Unfortunately, there is as yet no reversal agent for the drug. Due to inadequate